Latest News
A team of researchers—including Yale School of Medicine’s Sulayman D. Dib-Hajj, PhD, senior research scientist in neurology, Stephen G. Waxman, MD, PhD, professor of neurology, and Lakshmi Bangalore, PhD, lecturer in neurology—has been awarded funding through the NIH HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development.
- February 22, 2021Source: Yale News
Intravenous injection of bone marrow derived stem cells (MSCs) in patients with spinal cord injuries led to significant improvement in motor functions, researchers from Yale University and Japan report Feb. 18 in the Journal of Clinical Neurology and Neurosurgery.
- October 23, 2019
Scientists at Yale School of Medicine and Veterans Affairs Connecticut Healthcare System show at single-molecule resolution how nerve cells build their electrically excitable membranes.
- December 05, 2018
Scientists at the Yale School of Medicine and Veterans Affairs Connecticut Healthcare System have successfully demonstrated that it is possible to pinpoint genes that contribute to inter-individual differences in pain.
- November 03, 2018
The Society for Neuroscience (SfN) has announced that Stephen G. Waxman, MD, PhD, Bridget M. Flaherty Professor of Neurology and professor of neurobiology and of pharmacology, is this year's recipient of its Julius Axelrod Prize.
- April 18, 2017Source: Wired
On a scale of 1 to 10, how would you rate your pain? Would you say it aches, or would you say it stabs? Does it burn, or does it pinch?
- October 13, 2016Source: Yale Medicine
This is just one example of how Yale School of Medicine researchers and clinicians are pursuing innovations that could both improve treatment of opioid addiction and introduce new painkillers that are effective yet not addictive.
- April 18, 2016
Researchers at the Yale School of Medicine and the VA Connecticut Healthcare System have successfully tailored a personalized treatment approach for chronic pain in a severe pain syndrome known as inherited erythromelalgia.
- March 11, 2016Source: The Pharmaceutical Journal
Following intriguing genetic discoveries in people with extreme sensitivity to pain, as well as some families who feel no pain at all, researchers and drug companies are optimistic that blocking a sodium channel called Nav1.7 may lead to a new generation of more sophisticated painkillers. Meanwhile, however, there is still debate about the underlying mechanism of Nav1.7 in pain.
- November 13, 2012
An investigation into the molecular causes of a debilitating condition known as “Man on Fire Syndrome” has led Yale researchers to develop a strategy that may lead to personalized pain therapy and predict which chronic pain patients will respond to treatment.